UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________________________

FORM 8-K

_______________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~May~~July 161, 2016

_______________________________________

ROCK CREEK PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

_______________________________________

Delaware

(State or other jurisdiction of incorporation)

000-15324

(Commission File Number)

52-1402131

(IRS Employer Identification No.)

2040 Whitfield Avenue, Suite 300

Sarasota, Florida 34243

(Address of principal executive offices, including zip code)

844-727-0727

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Delaware (State or other jurisdiction of incorporation) 000-15324 (Commission File Number) 52-1402131 (IRS Employer Identification No.)

2040 Whitfield Avenue, Suite 300

Sarasota, Florida 34243

(Address of principal executive offices, including zip code)

(804) 527-1970

(Registrant’s telephone number, including area code)

_______________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 25.02. ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~May~~July 161 and July 5, 2016, respectively, Mr. Scott Sensenbrenner and Ms. Sunitha Chundru Samuel resigned as directors of Rock Creek Pharmaceuticals, Inc. (the “Company”). ~~issued~~Neither aof ~~press~~their ~~release~~resignations ~~announcing~~were ~~its~~due ~~financial~~to ~~results~~a ~~for~~disagreement with the ~~first~~Company ~~quarter~~on ~~ended~~any ~~March~~matter ~~31,~~relating ~~2016.~~to ~~A copy of~~ the ~~press~~Company’s ~~release~~operations, ispolicies, ~~furnished~~or ~~as Exhibit 99~~practices.~~2 to this Current Report on Form 8-K.~~

The information furnished in this Item 2.02, including Exhibit 99.2, is not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. This information will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

Item 7.01. Regulation FD Disclosure.

Attached as Exhibit 99.1 to this Current Report on Form 8-K is an updated investor presentation that Rock Creek Pharmaceuticals, Inc. (the “Company”) may use in presentations to investors from time to time.

The information in this Item 7.01 shall not be treated as filed for purposes of the Securities Exchange Act of 1934, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Investor Presentation (May 2016).
99.2	Press Release, dated May 16, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ROCK CREEK PHARMACEUTICALS, INC.


	By:	/s/ Michael J. Mullan
		Michael J. Mullan
		Chairman of the Board and Chief Executive Officer

Date: ~~May~~July 168, 2016

Filing Compare · ROCK CREEK PHARMACEUTICALS, INC.